文献速递药物不良反应与药物警戒特殊人群用药

利用ASSET工具分析利益相关者意见以优化EU丙戊酸风险评估中的风险最小化措施

Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET).
PubMed 文献 · Drug Saf · 2020-10-30

本研究基于实施理论开发了ASSET工具,分析2017-18年EU丙戊酸致畸性评估中公开听证会及专门会议的利益相关者意见,发现患者与多数HCP意见高度一致,但HCP在知情选择、丙戊酸治疗地位、RMM适当性及RMM传递方面存在分歧。研究提出九项可试点的PRAC参与建议,涵盖与利益相关者商定适当RMM、基于ASSET构建意见输入及协作监测实施与评估。

要点

  • ASSET工具含6个域21个主题,可系统分析利益相关者风险最小化意见。
  • 患者与多数HCP意见高度一致,但HCP内部在知情选择等四方面存在分歧。
  • 提出九项PRAC可试点建议,强调协作商定RMM并监测实施。

核心结论

  • 基于实施理论的新方法有望增强监管机构、患者与HCP之间的对话并促进患者安全。

研究设计与样本

  • 开发了基于实施理论的ASSET工具,包含6个域21个主题,对2017-18年EU丙戊酸致畸性程序公开听证会及专门会议的利益相关者输入进行内容分析。
  • 研究注册号:EU PAS REGISTER NUMBER: EUPAS35947。

主要发现

  • 利益相关者提供了广泛的RMM建议,部分超出监管职权范围。
  • 患者与多数HCP意见显著趋同,但HCP在知情选择目标、丙戊酸治疗地位、RMM适当性及RMM向HCP和患者传递方面存在分歧。
  • 伦理方面对监管决策具有相关性,从RMM实施角度识别出关键输入缺口。

关键数值与推荐

  • 提出九项可试点的PRAC建议,涉及:(A)与利益相关者商定适当RMM并催化医疗领导力促进实施;(B)基于ASSET构建对RMM实施关键要素的利益相关者输入;(C)与所有利益相关者协作监测实施并评估RMM。

临床怎么用

  • 临床药师可参考ASSET框架系统收集患者与HCP对RMM的意见,促进风险最小化措施的适当性与实施。
  • 在丙戊酸等高风险药物管理中,关注HCP在知情选择和治疗地位上的分歧,加强沟通与教育。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Understanding the impact of regulatory actions for medicines and enablers/barriers for positive health outcomes is fundamental to effective risk minimisation measures (RMM). Therefore, the Impact Strategy of the European Union (EU) Pharmacovigilance Risk Assessment Committee (PRAC) includes engagement with patient communities and healthcare professional (HCP) bodies regarding RMM. However, there is uncertainty on how best to obtain stakeholder input. OBJECTIVES: The objectives of this study were to (1) analyse stakeholder input at a public hearing and dedicated meeting for the 2017-18 EU procedure on valproate teratogenicity and (2) draw proposals for enhancing PRAC engagement. METHODS: For the content analysis, the novel 'Analysing Stakeholder Safety Engagement Tool' (ASSET) was developed with 21 themes in six domains (appropriateness, access, audience, compatibility, integrability, time), based on implementation theories. RESULTS: Stakeholders provided a wide range of RMM proposals, some beyond the regulatory remit. Patients and most HCPs converged remarkably, but there was some divergence among HCPs on the informed choice objective, the therapeutic place of valproate, the RMM appropriateness, and RMM delivery to HCPs and patients. Ethical aspects emerged as relevant for regulatory decision making, and crucial input gaps were identified from an RMM implementation perspective. Nine pilotable proposals for PRAC were made regarding: (A) Agreeing on appropriate RMM with stakeholders and catalysing healthcare leadership for implementation; (B) Building-up stakeholder input on all elements critical to RMM implementation guided by the ASSET; and (C) Collaborating with all stakeholders for monitoring implementation and evaluating RMM. CONCLUSIONS: New implementation theory-based approaches are promising for enhancing the valuable dialogue between regulators, patients and HCPs and achieving patient safety. EU PAS REGISTER NUMBER: EUPAS35947.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Bahri P, Morales DR, Inoubli A, et al. Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Saf. 2020. PMID: 33125664. doi:10.1007/s40264-020-01005-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。